Lindbrook Capital, LLC Phathom Pharmaceuticals, Inc. Transaction History

Lindbrook Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	BUY	$7.28 - $14.32 $960 - $1,890	132 New	132 $1,000
Q4 2022 Jan 24, 2023	SELL	$9.18 - $11.53 $128 - $161	-14 Reduced 8.09%	159 $0
Q3 2022 Nov 10, 2022	BUY	$6.46 - $12.11 $820 - $1,537	127 Added 276.09%	173 $2,000
Q2 2022 Aug 01, 2022	SELL	$6.2 - $15.5 $564 - $1,410	-91 Reduced 66.42%	46 $0
Q1 2022 Apr 21, 2022	BUY	$11.55 - $20.06 $1,582 - $2,748	137 New	137 $2,000

144

73.6M

42.3K

45.7K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $272M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.